Telix Pharmaceuticals Limited
TLPPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | -0.2% | 214.5% | -32.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 48.6% | 64.9% | 65.6% | 79.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 2.7% | 11.5% | 7.3% | 7.1% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | -$0 | $0 | $0 | $0 |
| % Margin | -0.6% | 6.4% | 6.2% | 6.9% |
| EPS | -0.01 | 0.12 | 0.035 | 0.06 |
| % Growth | -108.6% | 243.8% | -42.1% | – |
| EPS Diluted | -0.01 | 0.11 | 0.033 | 0.06 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 1.5% | 12.9% | 21.3% | 8.2% |